
Scholar Rock Unveils New Phase 3 SAPPHIRE Data at 2025 MDA Conference
Scholar Rock Presents New Data from Phase 3 SAPPHIRE Trial at 2025 MDA Conference Scholar Rock, a leading late-stage biopharmaceutical company, has revealed promising new data from its Phase 3 SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical…